Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy
Kumudha Ramasubbu, MD*,
Jerry Estep, MD*,
Donna L. White, PhD, MPH ,
Anita Deswal, MD, MPH*,, and
Douglas L. Mann, MD*,*
* Section of Cardiology and the Winters Center for Heart Failure Research, Department of Medicine, Baylor College of Medicine and The Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, Texas
Houston Center for Quality of Care and Utilization Studies, Houston, Texas
Section of Cardiology, Michael E. DeBakey VA Medical Center, Houston, Texas.
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Cholesterol Biosynthesis and the Beneficial and Adverse Downstream Effects of Statin Treatment
Beneficial (gray background) and adverse (checkered background) downstream effects of statin treatment. eNOS = endothelial nitric oxide synthase; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; LPS = lipopolysaccharide; NAD(P)H = nicotinamide adenine dinucleotide phosphate; NF B = nuclear factor kappa B; PI3 = phosphatidylinositol-3; PP = pyrophosphate; tRNA = transfer ribonucleic acid.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Mortality Among Patients With Heart Failure: Ischemic and Nonischemic Etiology
(A) Adjusted mortality among patients with ischemic etiology (n = 62,273) using statins compared with those not using statins. (B) Mortality among patients with heart failure of nonischemic etiology (n = 31,551) using statins compared with those not using statins.
|
|
|
